Galmed Pharmaceuticals (Galmed Pharmaceuticals) Cash-to-Debt : 308.34 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Galmed Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was 308.34.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Galmed Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Galmed Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

GLMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 64.12 Med: 5154.17 Max: No Debt
Current: 308.34

During the past 12 years, Galmed Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 64.12. And the median was 5154.17.

GLMD's Cash-to-Debt is ranked better than
84.86% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs GLMD: 308.34

Galmed Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Galmed Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Galmed Pharmaceuticals Cash-to-Debt Chart

Galmed Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

214.46

235.58

152.03

64.12

308.34

Galmed Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															64.12	No Debt	No Debt	No Debt	308.34

Competitive Comparison of Galmed Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Galmed Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galmed Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's Cash-to-Debt falls into.

Galmed Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Galmed Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	12.642	/	(0.041	+	0)
	=	308.34

Galmed Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	12.642	/	(0.041	+	0)
	=	308.34

Galmed Pharmaceuticals (NAS:GLMD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Galmed Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Galmed Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Galmed Pharmaceuticals (Galmed Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (NAS:GLMD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

GPH:Germany

Address

16 Tiomkin Street, Tel Aviv, ISR, 6578317

Website

https://www.galmedpharma.com

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.